Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms, Nerve Tissue 2Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 275pembrolizumab 267Carboplatin 190Cyclophosphamide 185Biopsy 178Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 123fludarabine 122Nivolumab 117Radiotherapy 113Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 88Capecitabine 88Dexamethasone 85Drug Therapy 76Pemetrexed 75Rituximab 73durvalumab 71Leucovorin 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 67atezolizumab 64Doxorubicin 64Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × contrast agent BR1 × 90 days × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Phase 3 Recruiting
32 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡